StockData
Immunovant, Inc. logo

Immunovant, Inc. (IMVT) stock

IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30
$33.21−0.07 (-0.21%)

Close on Nov 17, 2026Market cap $6.86BP/E –Yield –

Immunovant r&d expenses

Research and development expenses are spending on new products and technology.

Immunovant's R&D Expenses for the twelve months ending Jun 30, 2026 was $498.09M, up 28.8% year over year. For fiscal 2026 it was $456.66M, up 26.5% from the year before. The highest annual figure on record is $456.66M in fiscal 2026.

Annual r&d expenses

PeriodPeriod endValueChange
FY2026Mar 31, 2026$456.66M+26.5%
FY2025Mar 31, 2025$360.92M+69.5%
FY2024Mar 31, 2024$212.93M+32.9%
FY2023Mar 31, 2023$160.26M+57.4%
FY2022Mar 31, 2022$101.81M+48.4%
FY2021Mar 31, 2021$68.60M+43.1%
FY2020Mar 31, 2020$47.93M+86.2%
FY2019Mar 31, 2019$25.73M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ2 2026Jun 30, 2026$142.63M+40.9%
Q4 FY2026CQ1 2026Mar 31, 2026$142.29M+51.9%
Q3 FY2026CQ4 2025Dec 31, 2025$98.92M+4.7%
Q2 FY2026CQ3 2025Sep 30, 2025$114.25M+17.5%
Q1 FY2026CQ2 2025Jun 30, 2025$101.20M+34.1%
Q4 FY2025CQ1 2025Mar 31, 2025$93.65M+41.8%
Q3 FY2025CQ4 2024Dec 31, 2024$94.52M+95.5%
Q2 FY2025CQ3 2024Sep 30, 2024$97.27M+102.8%
Q1 FY2025CQ2 2024Jun 30, 2024$75.47M+49.2%
Q4 FY2024CQ1 2024Mar 31, 2024$66.06M+27.4%
Q3 FY2024CQ4 2023Dec 31, 2023$48.34M+14.4%
Q2 FY2024CQ3 2023Sep 30, 2023$47.96M+27.1%
Q1 FY2024CQ2 2023Jun 30, 2023$50.58M+77.9%
Q4 FY2023CQ1 2023Mar 31, 2023$51.84M+62.1%
Q3 FY2023CQ4 2022Dec 31, 2022$42.25M+42.0%
Q2 FY2023CQ3 2022Sep 30, 2022$37.74M+76.7%
Q1 FY2023CQ2 2022Jun 30, 2022$28.43M+52.0%
Q4 FY2022CQ1 2022Mar 31, 2022$31.99M+71.8%
Q3 FY2022CQ4 2021Dec 31, 2021$29.76M+41.1%
Q2 FY2022CQ3 2021Sep 30, 2021$21.36M+78.4%
Q1 FY2022CQ2 2021Jun 30, 2021$18.71M+10.5%
Q4 FY2021CQ1 2021Mar 31, 2021$18.62M-2.6%
Q3 FY2021CQ4 2020Dec 31, 2020$21.09M+14.2%
Q2 FY2021CQ3 2020Sep 30, 2020$11.98M+50.3%
Q1 FY2021CQ2 2020Jun 30, 2020$16.92M+120.3%
Q4 FY2020CQ1 2020Mar 31, 2020$19.12M–
Q1 FY2020CQ2 2019Jun 30, 2019$18.48M–
Q4 FY2019CQ1 2019Mar 31, 2019$7.97M–
Q3 FY2019CQ4 2018Dec 31, 2018$7.68M–

More Immunovant figures

See a number that looks wrong?